Panitumumab in the treatment of colorectal carcinoma


MUDr. Stanislav Batko

Radioterapeuticko-onkologické oddělení 2. LF UK a FN v Motole, Praha



This article reviews the efficacy panitumumab (Vectibix) in the treatment of metastatic colorectal carcinoma. Fist study published was PRIME in which panitumumab plus FOLFOX compared to chemotherapy alone prolonged overall survival in patients with non-resectable metastatic colorectal cancer (mCRC), furthermore it showed trend towards higher resection rate in patients with liver limited disease (LLD). The PEAK trial was comparing panitumumab and bevacizumab with chemotherapy backbone. Both overall survival and progression-free survival favored panitumumab compared to bevacizumab. PLANET trial was exploring potential of panitumumab to enhance overall response rate and allow for more curative resections in LLD population of mCRC patients. PLANET trial provided evidence high resectability and long overall survival. VOLFI trial represents a reasoned step in searching for more potent combination therapy. In randomized manner it compared FOLFOXIRI alone to FOLFOXIRI plus panitumumab. This study met its primary point, which was ORR, furthermore it showed greatly increased resectability in panitumumab arm and suggested better overall survival. Panitumumab plus FOLFOXIRI pose viable and efficient option for patients with mCRC, where deep tumor response could open way to surgical resection. VALENTINO study shed light on different maintenance strategies in 1st line mCRC after induction FOLFOX + panitumumab. Fluorouracil + leucovorin + panitumumab yielded better results in terms of 10-month PFS compared to panitumumab monotherapy.


Key words

panitumumab, PRIME, PLANET, PEAK, VOLFI, metastatic colorectal cancer resectability, ORR, OS, PFS, LLD



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...